Dr. Sallman on the Examination of Magrolimab in AML

David Sallman, MD, discusses the examination of magrolimab in acute myeloid leukemia.

David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, discusses the examination of magrolimab in acute myeloid leukemia (AML).

One clinical trial investigating magrolimab is the phase 3 ENHANCE-2 trial (NCT04778397) in patients with TP53-mutant AML. This patient population has been historically associated with poor outcomes, whether they were treated with venetoclax (Venclexta) plus a hypomethylating agent, or intensive chemotherapy, Sallman says. The 3 arms of the trial are investigating magrolimab plus azacytidine, vs physician's choice of venetoclax plus azacitidine or intensive 7+3 chemotherapy, Sallman explains.

Notably, the primary end point of overall survival will focus on the magrolimab plus azacytidine and venetoclax plus azacytidine arms, Sallman says. Patients with TP53-mutated AML have not gained any significant benefit from venetoclax-based regimens, and ENHANCE-2 will aim to establish a new treatment backbone for this population, Sallman adds.

The phase 3 ENHANCE-3 trial (NCT05079230) is evaluating magrolimab plus venetoclax and azacytidine, vs placebo plus venetoclax and azacytidine, in elderly patients with AML and younger patients with AML and comorbidities, Sallman continues. The goal for ENHANCE-3 will be to establish a new standard-of-care therapy for this target population, which would also include a proportion of patients with TP53-mutated AML, Sallman concludes.